David J. Wambeke - 27 Aug 2026 Form 4 Insider Report for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC)

Reporting relationship: Chief Business Officer
Issuer ticker: NMTC
Reported as of: 27 Aug 2026
Net transaction value: +$66,999
SEC form: 4
Accepted by SEC: 08 Sep 2026, 08:31:48 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Emily Johns, by Power of Attorney

Key filing fact

David J. Wambeke filed Form 4 for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) on 08 Sep 2026.

Key facts

This page summarizes David J. Wambeke's Form 4 filing for NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 08 Sep 2026, 08:31.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: +$66,999.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971798 Primary reporting owner

Wambeke David J.

Relationship: Chief Business Officer
Address: C/O NEUROONE MEDICAL TECHNOLOGIES CORP, 7599 ANAGRAM DRIVE, EDEN PRAIRIE
Signature: /s/ Emily Johns, by Power of Attorney
Signature date: 08 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NMTC transaction

Common Stock

Purchase

Transaction value: $66,999
Shares: +33,333
Change %: +20%
Price: $2.01
Shares after: 199,999
Date: 27 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NMTC transaction Derivative

Option to Purchase Common Stock

Award

Transaction value
Shares: +35,000
Change %
Price: $0.000000^*
Shares after: 35,000
Date: 28 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 35,000
Exercise price: $1.77
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The price represents the weighted average price of the multiple transactions reported on this line. The shares were sold at prices ranging from $2.00 and $2.017 per share. Upon request by the SEC staff, the issuer or any securityholder of the issuer, the reporting person will provide full information regarding the number of shares sold at each separate price.

Footnote F2

25% will vest on August 28, 2027, and the remaining 75% will vest in 12 equal quarterly installments.